Monoclonal gammopathies of clinical significance

Research output: Contribution to journalArticlepeer-review

Abstract

“Monoclonal gammopathy of clinical significance” (MGCS) is the term used to describe nonmalignant monoclonal gammopathies causing important disease. MGCS is the differential diagnosis for any patient presenting with what appears to be a monoclonal gammopathy of undetermined significance but is also experiencing other unexplained symptoms. Broadly, these conditions can be separated into symptoms and signs referable to the nerves, the kidneys, and the skin. The first step in making these diagnoses is to consider them. With a particular condition in mind, the next step is to order those tests that can help confirm or dismiss a particular diagnosis. Nearly all of the renal and dermatologic conditions are diagnosed by renal and skin biopsies, respectively. The importance of a highly competent renal pathologist and dermatopathologist cannot be underestimated. Biopsy is less specific for the neuropathic conditions. Because several of the MGCSs are syndromes, recognizing other manifestations is also key. Treatment recommendations for many of these conditions are anecdotal because of their rarity, but for several of the conditions, IV immunoglobulin, rituximab, and plasma cell-directed therapy are the best options.

Original languageEnglish (US)
Pages (from-to)380-388
Number of pages9
JournalHematology (United States)
Volume20
Issue number1
DOIs
StatePublished - Dec 2020

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Monoclonal gammopathies of clinical significance'. Together they form a unique fingerprint.

Cite this